2025 Partners

Catalyst Capital Markets

Website: https://www.catalystcapmkts.com/

Catalyst Capital Markets is a specialized capital markets advisory firm dedicated to unlocking growth and opportunity for emerging and established companies. Founded by a team of seasoned senior executives with over 175 years of collective global experience, Catalyst Capital Markets delivers strategic guidance and transaction management across the full spectrum of capital markets activities. The firm’s expertise spans initial public offerings, follow-on transactions, direct listings, up listings, private placements, PIPEs, private credit, mezzanine debt, high-yield bonds, convertible securities, SPAC and De-SPAC advisory, and more.

With a proven track record of advising or executing on more than 1,000 debt and equity transactions over the past four decades, Catalyst Capital Markets leverages deep industry knowledge and a broad investor network to drive differentiated value and outcomes for its clients. The firm’s disciplined, client-focused approach is designed to optimize capital structures, facilitate fundraising, and support strategic corporate actions such as mergers, acquisitions, spin-outs, and divestitures. Headquartered in Bucks County, Pennsylvania, Catalyst Capital Markets is positioned as a trusted partner for companies navigating the complexities of today’s capital markets environment.

AOTI

Website: https://aotinc.net/

At AOTI, we are helping all people with chronic conditions get back to living their lives to the fullest. We do this by enhancing access to care, improving clinical outcomes and quality of life, and advancing health equity. AOTI is recognized as a leader in wound care technology around the world and is a founding member of the American Diabetes Association’s - Amputation Prevention Alliance. Our unique multi-modality Topical Wound Oxygen (TWO2) therapy has been proven through Randomized Controlled Trial and Real-World Evidence studies to significantly reduce both Hospitalizations and Amputations over 12 months. Using a combination of non-contact cyclical compression, humidification, and high-pressure delivery of oxygen, AOTI’s TWO2 therapy has shown to provide more effective and durable complete healing in a variety of different wound types, including Diabetic Foot Ulcers, Venous Leg Ulcers and Pressure Ulcers. TWO2 can be administered in any clinical setting or self-administered by the patient at home, overcoming common barriers to access and compliance, thus helping to advance health equity, while improving outcomes and reducing costs.

Amferia

Website: https://www.amferia.com/

Amferia was founded in 2018 as a spin-off from Chalmers University of Technology, Gothenburg, Sweden. Amferia’s proprietary technology is a new and effective antimicrobial material based on antimicrobial peptides that targets and rapidly kills bacteria upon contact, including numerous antimicrobial resistant bacteria like MRSA and MDR E. Coli.

The material is selective and targets only bacteria while being entirely non-toxic to human and animal cells. Today, the team has transformed this concept into a technology platform, with the first product being an antimicrobial wound care dressing for skin wound applications in human and animal health, supported by strong scientific data. Read more at www.amferia.com

Coldplasmatech

Website: https://coldplasmatech.com/

Coldplasmatech GmbH is a German MedTech innovator transforming wound care with cold atmospheric plasma technology. Based in Greifswald, the company developed the CPT® system – a unique, non-invasive therapy that promotes healing, combats multidrug-resistant bacteria, and stimulates tissue regeneration. The platform consists of the CPTpatch® and CPTcube®, enabling precise, localized treatment for chronic wounds, burns, and surgical sites. Coldplasmatech’s solution is CE-marked (Class IIb) and already in use at leading hospitals and outpatient CPT-Plasma-Competence-Centers in Europe. With strong clinical evidence, international partnerships, and a focus on scalable innovation, Coldplasmatech is redefining wound healing for modern healthcare.

JDL Access

Website: https://jdlaccess.com/

JDL ACCESS
Bridging the Gap to Market Adoption

JDL Access offers comprehensive reimbursement support services designed for medical technology companies.  Our mission is to bridge the medical technology gap from commercialization to coverage. We achieve this by creating tailored patient access programs that support individual case coverage, while also providing field market access services to drive broad positive coverage at the payer medical policy level. Through the strategic use of patient appeals and the expertise of our payer advocacy team, we accelerate payer adoption and ensure that groundbreaking medical technologies are accessible to the patients who need them most.

Merakris

Website: https://merakris.com/

Merakris Therapeutics is pioneering biologic drug development by leveraging exosomes, growth factors, and cell-derived proteins from immunologically privileged tissues. The company’s innovative platform harnesses these bioactive components—especially nano vesicles and cytokine-rich formulations—to drive wound healing and tissue regeneration.

Merakris has three commercial products and an active Phase 2b IND-stage drug candidate, MTX-001, a first-in-class, subcutaneous biologic injection for the treatment of venous leg ulcers (VLUs). MTX-001 is a cell-free amniotic wound care liquid that utilizes a potent mix of cytokines and regenerative proteins to initiate and regulate complex biological healing cascades.

RegenLab USA

Website: https://www.regenlabusa.com/

RegenLab USA LLC is a leading manufacturer specializing in advanced technologies for regenerative medicine, with a core focus on autologous platelet-rich plasma (PRP) therapies. Our commitment to patient safety, product innovation, and clinical excellence is underscored by our achievement of MDSAP certification, demonstrating adherence to the highest international quality and regulatory standards.

With a fully in-house sterilization process and a new state-of-the-art manufacturing facility in Jersey City, New Jersey, RegenLab ensures precise control over product sterility, consistency, and integrity—delivering manufacturing excellence rare within the industry. Our proprietary PRP technology is backed by extensive intellectual property coverage, supported by over 300 scientific publications and five clinical study books that validate our leadership in regenerative science.

As we continue to expand our reach, we are actively seeking partnership opportunities with healthcare providers, distributors, and research institutions dedicated to advancing the field of regenerative therapies. RegenLab USA LLC remains steadfast in its mission to deliver scientifically grounded solutions that empower medical innovation and improve patient outcomes.

SolasCure

Website: https://www.solascure.com/

SolasCure is developing Aurase Wound Gel (AWG), a novel enzymatic debrider designed to improve debridement and biofilm management in chronic wound care. AWG utilizes tarumase, an enzyme inspired by larval therapy, to offer effective, selective, and continuous debridement while protecting healthy tissue. By consistently clearing wounds of slough and biofilm, AWG fosters an optimal healing environment. Unlike conventional methods, AWG's safety profile supports 'maintenance' debridement to prevent the reoccurrence of slough and infection, making it a strong fit for current wound care protocols. This approach aims for faster healing, better patient outcomes, and potential cost savings for healthcare systems.

Transdiagen

Website: https://www.transdiagen.com/

Transdiagen (TDG) is a precision medicine company developing diagnostics and drugs for chronic wound healing and tissue regeneration.  TDG’s Drug-Target Interaction (DTI) prediction network utilises patented gene signature biomarkers to power their drug discovery platform.

TDG have developed a range of PCR based, gene expression diagnostics.  Our most advanced diagnostic “WD14” stratifies venous leg ulcer patients into those that will heal under standard of care from those that will not.  TDG also have a range of drug development programs generated by our DTI prediction network, with patents granted for our lead drug candidate.

TDG has now launched a service whereby data generated from our proprietary models, (molecular mechanisms of disease understanding) for drug and device development can be accessed across a range of indications and interventions from discovery through to post-market analysis.  Partnering with TDG and accessing data from our In Vivo and Ex Vivo models provide:

• Cell function mechanisms of action for chronic wounds,
• Functional insights that support product development and performance improvements, &
• Route to incremental IP and additional product lines.

Tiger Wound Care

Website: https://tigerbiosciences.com/

Zero Gravity Skin

Website: https://www.zerogravityskin.com/

ZERO GRAVITY SKIN was founded with one goal in mind; to develop and deliver the safest and most effective pain management and anti-aging Medical devices to consumers across the globe.
Zero Gravity is committed to produce the most effective LED (Light Emitting Diodes) light therapy for chronic pain and facial skin rejuvenation in the industry.
The sophisticated technology behind InfraRed Light Therapy is supported by many leading board
certified Dermatologists and Plastic Surgeons across the globe.

Zero Gravity devices are FDA-Cleared Class 11 medical devices.